Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 7/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4592585 | 0.81 | CYP1A2 (0.49) | ALDH1A1KDM4ECYP1A2CYP3A4MAPT | |
| SCHEMBL11451306 | 0.81 | ALDH1A1 (0.41) | ALDH1A1KDM4ECYP1A2CYP3A4MAPT | |
| SCHEMBL11442064 | 0.81 | CYP1A2 (0.49) | ALDH1A1KDM4ECYP1A2CYP3A4MAPT | |
| SCHEMBL11524479 | 0.78 | ALDH1A1 (0.40) | ALDH1A1KDM4ECYP1A2CYP3A4MAPT | |
| SCHEMBL92282 | 0.72 | — | — | |
| SCHEMBL24591296 | 0.72 | ALDH1A1 (0.39) | ALDH1A1KDM4ECYP1A2CYP3A4MAPT | |
| SCHEMBL11524516 | 0.69 | CES2 (0.37) | ALDH1A1KDM4ECYP1A2CYP3A4MAPT | |
| SCHEMBL166075 | 0.69 | — | — | |
| SCHEMBL2059274 | 0.68 | PTGS1 (0.76) | CYP1A2CYP3A4MAPTCYP2C19TSHR | |
| SCHEMBL30463820 | 0.68 | PTGS1 (0.76) | CYP1A2CYP3A4MAPTCYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | ALDH1A1 2806/4885KDM4E 1862/4885CYP1A2 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.